Page 7 - Polypeptide Group News Today

3 Min Read ZURICH (Reuters) -Shares in aircraft components maker Montana Aerospace soared nearly 18% on its debut on the Swiss bourse on Wednesday, giving it a higher-than-expected market capitalisation of about 1.4 billion Swiss francs ($1.5 billion). The Austrian-Swiss company, whose customers include Boeing and Airbus, saw its shares rise to 30.60 Swiss francs ($33.16) in early trading, well above a list price of 25.65 Swiss francs. The increase added roughly 200 million francs to the compan...

EQS Group-Ad-hoc: PolyPeptide Group / Schlagwort(e): Börsengang PolyPeptide Group gibt vollständige Ausübung der Mehrzuteilungsoption bekannt 05.05.2021 / 17:40 CET/CEST Veröffentlichung einer

EQS-Adhoc: PolyPeptide Group AG: PolyPeptide Group gibt vollständige Ausübung der Mehrzuteilungsoption bekannt PolyPeptide Group gibt vollständige Ausübung der Mehrzuteilungsoption bekannt 05.05.2021 / 17:40 CET/CEST Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN ...

Investegate announcements from Credit Suisse (Eur), Post Stabilisation Notice - PolyPeptide Group AG

Mehrzuteilungsoption bekannt EQS Group-Ad-hoc: PolyPeptide Group / Schlagwort(e): Börsengang PolyPeptide Group gibt vollständige Ausübung der Mehrzuteilungsoption bekannt 05.05.2021 / 17:40 CET/CEST Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. ------------------------------------------------------------ ...

  About PolyPeptide Group PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and I...

International PolyPeptide Group Chooses SIX For Its IPO Date 29/04/2021 Today, PolyPeptide Group AG (Ticker "PPGN"), a global leader in peptide development and manufacturing, listed its shares on the Swiss Stock Exchange. The opening price was CHF 72.50 per share, resulting in a market capitalization of CHF 2.4 billion. With PolyPeptide Group, SIX welcomes another company from the life sciences sector, further expanding its strong peer group and strengthening its position as Europe’s lea...

EQS-News: PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und beginnt Handel an der Schweizer Börse PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und beginnt Handel an der Schweizer Börse 29.04.2021 / 07:00 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. FOR RELEA...

The IPO of PolyPeptide Group, the Swiss pharmaceutical ingredients company, is set to be priced at Sfr64, above the midpoint of the initial Sfr57 to Sfr68 range, according to sources close to the deal.

infinityApril 24, 2021 1 The Global Bioactive Peptides Market Report recently published by Infinity Business Insights is a professional and in-depth study on the current state of the industry. Different exploratory techniques such as qualitative and quantitative analysis have been used to give data accurately. For a better understanding of the customers, it uses effective graphical presentation techniques such as graphs, charts, tables as well as pictures. The report is studied with various a...